Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,935 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP. Hayashi M, et al. Among authors: taguchi t. Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596. Anticancer Res. 2019. PMID: 31366522 Clinical Trial.
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N; JONIE Study Group. Hasegawa Y, et al. Among authors: taguchi t. PLoS One. 2015 Dec 3;10(12):e0143643. doi: 10.1371/journal.pone.0143643. eCollection 2015. PLoS One. 2015. PMID: 26633806 Free PMC article. Clinical Trial.
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Nakatsukasa K, et al. Among authors: taguchi t. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. Breast Cancer. 2019. PMID: 30054855 Clinical Trial.
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Sakaguchi K, et al. Among authors: taguchi t. Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770. Medicine (Baltimore). 2019. PMID: 31393399 Free PMC article. Clinical Trial.
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M, Noguchi S. Takahashi S, et al. Among authors: taguchi t. Breast Cancer Res Treat. 2012 Jun;133(2):685-93. doi: 10.1007/s10549-012-1973-0. Epub 2012 Feb 4. Breast Cancer Res Treat. 2012. PMID: 22307266 Clinical Trial.
Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Yamada K, Kaise H, Taguchi T, Horiguchi J, Takao S, Suzuki M, Kubota T, Miura D, Narui K, Tawaraya K, Machida Y, Akazawa K, Kohno N, Ishikawa T; JONIE Study Group. Yamada K, et al. Among authors: taguchi t. J Bone Miner Metab. 2022 Nov;40(6):998-1006. doi: 10.1007/s00774-022-01366-y. Epub 2022 Aug 30. J Bone Miner Metab. 2022. PMID: 36042056 Clinical Trial.
Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
Sakaguchi K, Nakatsukasa K, Koyama H, Kato M, Sakuyama A, Matsuda T, Tsunoda N, Fujiwara I, Yamaguchi M, Tanaka H, Onishi K, Onishi M, Yoshino Y, Kikuchi T, Taguchi T. Sakaguchi K, et al. Among authors: taguchi t. Anticancer Res. 2018 Jul;38(7):4073-4081. doi: 10.21873/anticanres.12697. Anticancer Res. 2018. PMID: 29970533 Clinical Trial.
2,935 results